Coronavirus update: WHO says plasma treatment touted as breakthrough by Trump is unproven, advises
( MarketWatch )
The World Health Organization said Monday the plasma therapy that received an emergency-use authorization from the administration of President Donald Trump — which hailed it on Sunday as a “breakthrough” in treating COVID-19 — is still unproven and cautioned that the there is “very low evidence” that it is safe and effective.
Dr. Soumya Swaminathan, chief scientist at the WHO, told reporters at a Monday briefing that while there are many clinical trials seeking to evaluate the use of blood plasma from patients of the deadly illness who have recovered, only a few have reported results.
“The results are not conclusive,” Swaminathan told the briefing. “The trials have been relatively small, and the results in some cases point to some benefit but have not been conclusive.”
Other experts agreed. The American Society for Biochemistry and Molecular Biology said just last week that the Food and Drug Administration was holding back on issuing the EUA, which is not a full approval, because government scientists were awaiting trial results. “President Trump is once again putting his political goals ahead of the health and well-being of the American public,” the ASBMB said in a statement. The president for some time “has pushed a narrative that scientists are slow-walking treatments for COVID-19 until after the November election in an effort to hurt his re-election chances. These accusations are baseless and dangerously politicize science,” said the statement.
The statement cautioned that blood-plasma transfusions “are not without risks, including death, and scientists should be afforded the opportunity to prove the benefits outweigh the risks.” Former FDA Commissioner Scott Gottlieb also dismissed talk of a slowdown in developing COVID-19 treatment and therapies.
“I firmly reject the idea they would slow-walk anything or accelerate anything based on any political consideration or any consideration other than what is best for the public health and a real sense of mission to patients,” Gottlieb told CBS’s “Face the Nation,” the Associated Press reported.